UniProt Q9NYY3 · PDB · AlphaFold · Substrate: Casein · Clone: full length
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Defactinib | 55.0% | 45.0% | 92.68 | 0.450 |
| 2 | Rabusertib | 26.5% | 73.5% | 98.74 | 0.687 |
| 3 | Fostamatinib | 22.5% | 77.5% | 96.74 | 0.613 |
| 4 | Bosutinib | 20.7% | 79.3% | 87.22 | 0.555 |
| 5 | Neratinib | 17.1% | 82.9% | 93.18 | 0.597 |
| 6 | Vemurafenib | 14.5% | 85.5% | 96.49 | 0.598 |
| 7 | Ceritinib | 12.9% | 87.1% | 95.44 | 0.618 |
| 8 | Sorafenib | 11.8% | 88.2% | 96.72 | 0.776 |
| 9 | Repotrectinib | 11.2% | 88.8% | 84.21 | 0.608 |
| 10 | Lapatinib | 11.1% | 88.9% | 99.25 | 0.616 |
| 11 | Canertinib | 10.6% | 89.4% | 96.49 | 0.671 |
| 12 | Pexidartinib | 10.2% | 89.8% | 99.49 | 0.631 |
| 13 | Regorafenib | 9.4% | 90.6% | 95.99 | 0.719 |
| 14 | Umbralisib | 9.2% | 90.8% | 98.74 | 0.670 |
| 15 | Quizartinib | 9.1% | 90.9% | 99.50 | 0.737 |
| 16 | Ruxolitinib | 8.8% | 91.2% | 98.25 | 0.592 |
| 17 | Ripretinib | 8.7% | 91.3% | 92.95 | 0.674 |
| 18 | Lazertinib | 8.2% | 91.8% | 97.47 | 0.674 |
| 19 | Zanubrutinib | 7.7% | 92.3% | 98.24 | 0.788 |
| 20 | Paxalisib | 7.7% | 92.3% | 99.75 | 0.609 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 6.86
- Epithelial log2(TPM+1): 4.44
- Fold change: 2.42
- Status: Upregulated
Selectivity landscape vs inhibition on PLK2
Each point is one of the 92 approved drugs; color = inhibition % on PLK2.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…